<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27403406</article-id><article-id pub-id-type="pmc">4926553</article-id><article-id pub-id-type="publisher-id">ABR-5-111</article-id><article-id pub-id-type="doi">10.4103/2277-9175.184277</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Berjis</surname><given-names>Nezamoddin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Soheilipour</surname><given-names>Saeed</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Musavi</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Hashemi</surname><given-names>Seyed Mostafa</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Otorhinolaryngology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Alireza Musavi, Department of Otolarhngology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="medic@sgpco.com">medic@sgpco.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2016</year></pub-date><volume>5</volume><elocation-id>111</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Berjis.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>During the past years various drugs have been used for sudden sensorineural hearing loss (SSNHL) treatment including steroids that are shown to be beneficial. Directed delivery of high doses of steroids into the inner ear is suggested for its potential and known as intratympanic steroids therapy (IST). Despite the use of dexamethasone and methylprednisolone as the traditional treatments, there are still debates about the optimal dosage, preferred drug, and the route of administration.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>We performed a randomized clinical trial study in which 50 patients suffering from SSNHL and resistant to standard therapy were employed. Each patient took 0.5 ml methylprednisolone (40 mg/mg) along with bicarbonate or dexamethasone (4 mg/mL) through direct intratympanic injection. This method was performed and scheduled once every 2 days for three times only for the dexamethasone receiving group. Hearing test was carried out and the results were analyzed according to a four-frequency (0.5, 1.0, 2.0, 3.0 kHz) pure tone average (PTA) and Siegel's criteria.</p></sec><sec id="st3"><title>Results:</title><p>According to Siegel's criteria, three out of 25 (12%) dexamethasone receiving patients were healed in 1 and 4 (16%), 9 (32%) were respectively recovered in Siegel's criteria 2, 3, and 9 (32%) showed no recovery. In the group receiving methylprednisolone, recovery was found in 6 (24%), 8 (32%), 7 (28%) patients in the Siegel's criteria 1, 2, 3, respectively, and in 4 (16%) patients no recovery was recorded. In methylprednisolone group, hearing was significantly improved compared to the dexamethasone group (<italic>P</italic> &#x0003c; 0.05). The general hearing improvement rate was 84% in methylprednisolone receiving patients showing a significantly higher improvement than 64% in the dexamethasone group.</p></sec><sec id="st4"><title>Conclusions:</title><p>Topical intratympanic treatment with methylprednisolone is safe and an effective treatment approach for those SSNHL cases that are refractory to the common therapies by Dexamethasone.</p></sec></abstract><kwd-group><kwd>Dexamethasone</kwd><kwd>intratympanic injection</kwd><kwd>methylprednisolone</kwd><kwd>steroid therapy</kwd><kwd>sudden sensorineural hearing loss</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Sudden sensorineural hearing loss (SSNHL) is a common emergency in Otology, known as an acute unilateral deafness, with a sharp onset (usually during 3 days), with more than 30 dB hearing loss at three subsequent frequencies.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] To observe the etiology of different diseases, various cases including autoimmune inflammation, viral cochleitis, and inner ear membrane rupture have been studied.[<xref rid="ref3" ref-type="bibr">3</xref>] The most convincing causes are viral and vascular etiologies. The natural background of SNNHL is still unknown; spontaneous recovery happens in almost 30% of cases and it will recover mostly during the first 2 weeks after its onset, and it contains partial response.</p><p>Many factors seem to influence recovery; the degree of hearing loss, the audiogram pattern, the existence of vertigo, and the duration between the onset and treatment of SNHL are probably the most important factors.</p><p>Different therapies have been tried for SSNHL, none of which was effective. Hyperbaric oxygen, vasodilator drugs, agents that decrease blood viscosity and magnesium, are some examples of previously tested SSNHL treatments. Some studies present that steroids might be effective,[<xref rid="ref1" ref-type="bibr">1</xref>] while more results are needed. Systemic steroids with prompt administration increase the rate of hearing recovery.[<xref rid="ref4" ref-type="bibr">4</xref>] Needless to say that steroids in high doses can be followed by systemic effects; hence, it so cannot be used for all patients. Several mechanisms of action are recognized for corticosteroids including anti-inflammatory action, immune suppression, membrane stabilization, increased perfusion, and ion balance regulation.[<xref rid="ref11" ref-type="bibr">11</xref>] It has been shown that steroids can also be effective if no immune disorder is demonstrated.[<xref rid="ref12" ref-type="bibr">12</xref>]</p><p>The transtympanic route presents two main advantages: (1) it produces significantly higher perilymph concentrations of steroids than intravenous or oral administration; (2) it is possible to reduce the side effects due to systemic absorption. Effectiveness of local application of steroids in SSNHL, M&#x000e9;ni&#x000e8;re's disease, and in other inner ear conditions has been reported by many authors.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] Although dexamethasone and methylprednisolone were used traditionally but optimal dosage, drug, and route of administration still remain a matter of debate. Based on these considerations, we started treating SSNHL patients with transtympanic Dexamethasone versus methylprednisolone in order to better understand the real effectiveness of this treatment.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>In the randomized, clinical trial study, we enrolled 50 consecutive patients admitted to Otolaryngology Head and Neck Surgery Department of Isfahan Medical University in two hospital Kashani and Al-Zahra between February 2012 and January 2013, all diagnosed with SSNHL and nonresponsive to standard therapy. Inclusion and exclusion criteria were: (1) 30 dB loss in three consecutive frequencies in &#x0003c;72 h, (2) normal otoscopic examination, (3) no history of chronic otitis media, (4) no history of trauma (head, acoustic, or barometric), (5) no history of Meniere's disease, hydrops, or fluctuating hearing loss, (6) no history of meningitis, (7) no history of prior ear surgery, (8) no history of radiation, (9) no exposure to ototoxic mediations, (10) no response to conventional therapies included the systemic steroids therapy, neural nutrients administration, vascular dilator, anticoagulator, or hyperbaric oxygen therapy, and (11) no take any conventional therapies in two previous weeks.</p><p>Auditory function was determined by pure-tone audiometry; the mean hearing levels were expressed as the average of hearing thresholds at 0.5, 1, 2, and 3 kHz (4-tone average) (PTA), according to the guidelines of the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology &#x02014; Head and Neck Surgery. Auditory measurements were performed before and 1 month after the treatment, according to Siegel's criteria for hearing improvement.[<xref rid="ref14" ref-type="bibr">14</xref>] &#x02018;Complete recovery&#x02019; was defined as more than 30 dB hearing gain and as final hearing better than 25 dB, &#x02018;partial recovery&#x02019; as more than 15 dB hearing gain and as final hearing between 25 and 45 dB, &#x02018;slight improvement&#x02019; as more than 15 dB hearing gain but with a final hearing poorer than 45 dB, and &#x02018;no improvement&#x02019; as less than 15 dB hearing gain and final hearing poorer than 75 dB. The operative procedure of intratympanic steroid injection was performed under a microscope and with patient in supine position. After the surgeon confirmed the intact tympanic membrane and middle ear status, topical anesthesia was administered with a cotton ball soaked with lidocaine 10% pump spray (Xylocaine), which was applied on the tympanic membrane for 20 min. While the patient tilted the head 45&#x000b0; to the healthy side, a 25-gauge spinal needle was introduced into the posteroinferior portion of membrane and 0.5 ml of methylprednisolone (40 mg/ml) with bicarbonate or dexamethasone (4 mg/ml) was instilled through this site in each group, respectively. This procedure was carried out three times, once every 3 days, only for the dexamethasone group. The patient was instructed to avoid swallowing or moving for 30 min, remaining in the same position.</p><p>Statistical tests were performed using Mann-Whitney U test for categorical variables and Student's t-test for continuous variables (SPSS ver. 14.0, SPSS Inc., Chicago, IL, USA).</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>The demographics and audiological data of the patients are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. There were 29 men (58%) and 21 women (42%). The mean age at enrolment for all patients was 45.88 +/&#x02013; 14.97 years and ranged from 16 to 70 years. The mean age for the men was 47.24 +/&#x02013; 15.6 years and for the women was 44 +/&#x02013; 14.21 years. Age, sex, degree of initial hearing loss, and the time delay between onset of hearing loss and treatment were not statistically significant different between the dexamethasone and methylprednisolone group [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>General characteristics of patients</p></caption><graphic xlink:href="ABR-5-111-g001"/></table-wrap><p>Final hearing improvement on the basis of Siegel's criteria is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. For statistical analysis, improvement was defined as hearing results categorized as I, II, and III of Siegel's criteria and no improvement was defined as hearing results categorized as IV of Siegel's criteria.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Hearing improvement based on Siegel's criteria in Dexamethasone and Methylprednisolone groups</p></caption><graphic xlink:href="ABR-5-111-g002"/></fig><p>Three of twenty-five patients (12%) in dexamethasone group were recovered in Siegel's criteria I and 4 (16%), 9 (32%) were, respectively, recovered in Siegel's criteria II and III and 9 (32%) were not recovered. In the methylprednisolone group, 6 (24%), 8 (32%), 7 (28%) patients were recovered in the Siegel's criteria I, II, III, respectively, and 4 (16%) patients were not recovered. Statistical analysis shows a significant difference between dexamethasone and methylprednisolone groups based on Siegel's criteria (<italic>P</italic> &#x0003c; 0.05). The overall hearing improvement rate was 64% in the dexamethasone group, which was significantly higher than 84% in the methylprednisolone group. No unexpected adverse events and worsening in hearing occurred during the injection or follow-up period.</p></sec><sec sec-type="conclusions" id="sec1-4"><title>CONCLUSIONS</title><p>Clinically SSNHL, a common otologic emergency, has possibility of high spontaneous recovery, but all reports describing treatments indicate that early initiation of treatment will undoubtedly lead to improved prognoses. Because the etiology of SSNHL is not fully understood, there is no universal treatment modality.</p><p>Because of spontaneous recovery in SSNHL, it is difficult to determine if any therapeutic intervention actually improves the hearing. The natural history of untreated patients with SSNHL states that the recovery rates varies from 31% to 65%,[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] while the hearing recovery in treated patients ranges from 35% to 89%.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] These results may be related to different factors: the patient data, the type of steroid administration, the length of therapy, the severity of hearing loss, the duration from onset of symptoms to start of treatment, the variable treatment protocols, and the method of statistical analysis. At this time, steroids systematic administration is considered to be the most commonly accepted treatment for SSNHL.</p><p>The precise mechanism through which steroids may improve hearing remains unknown; both glucocorticoid and mineralocorticoid receptors may be found in the inner ear.[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref>] The main roles of steroids in the treatment of SSNHL are: (1) the protection of cochlea from the harmful effects of inflammatory mediators, such as the tumor necrosis factor (TNF-&#x003b1; and NF-&#x003ba;B) and cytokines (interleukin 1 and 6), which is elevated in infection and inflammation;[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] (2) increasing cochlear blood flow[<xref rid="ref20" ref-type="bibr">20</xref>] thereby avoiding cochlear ischemia;[<xref rid="ref23" ref-type="bibr">23</xref>] (3) avoiding noise-induced hearing loss;[<xref rid="ref24" ref-type="bibr">24</xref>] (4) regulating protein synthesis in the inner ear.[<xref rid="ref25" ref-type="bibr">25</xref>] There the vascular stria regulates Na/K secretion in order to maintain endocochlear potential; it is the most frequent site of injury in the SSNHL.[<xref rid="ref26" ref-type="bibr">26</xref>] Systemic steroid therapy improves vascular stria function and may preserve its morphology and therefore it has potential for recovering from SSNHL.[<xref rid="ref27" ref-type="bibr">27</xref>]</p><p>For the first time, Silverstein showed intratympanic steroids therapy (IST) was effective in the treatment of SSNHL[<xref rid="ref28" ref-type="bibr">28</xref>] that followed by several other reports.[<xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref><xref rid="ref31" ref-type="bibr">31</xref><xref rid="ref32" ref-type="bibr">32</xref><xref rid="ref33" ref-type="bibr">33</xref><xref rid="ref34" ref-type="bibr">34</xref><xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref><xref rid="ref37" ref-type="bibr">37</xref><xref rid="ref38" ref-type="bibr">38</xref>] It was demonstrated that intratympanic infusion of steroids leads to a much higher perilymphatic concentration, as compared to the systemic route.</p><p>Usually, intratympanic steroids are used in three main aims: (1) initial treatment, (2) adjuvant therapy given concomitantly with systemic steroids, and (3) salvage treatment after failure of standard therapy. However, according to several clinical trials,[<xref rid="ref31" ref-type="bibr">31</xref><xref rid="ref32" ref-type="bibr">32</xref><xref rid="ref33" ref-type="bibr">33</xref><xref rid="ref34" ref-type="bibr">34</xref>] IST, as first-line therapy, seems to be a valuable solution in refractory SSNHL, at least as effective as systemic steroids and can be a reasonable alternative for patients who are in the failure of intravenous treatment or cannot tolerate systemic therapy.[<xref rid="ref38" ref-type="bibr">38</xref><xref rid="ref39" ref-type="bibr">39</xref>]</p><p>The overall hearing improvement was observed in 21 of 25 methylprednisolone received patients (84%), which was significantly higher than 64% of 25 patients in dexamethasone group (<italic>P</italic> &#x0003c; 0.05). Dallan <italic>et al</italic>. reviewed the medical records of patients diagnosed with SSNHL and nonresponsive to standard therapy. These patients were treated with intratympanic methylprednisolone. They showed that 15 (55%) of 27 patients presented a useful improvement in the hearing status.[<xref rid="ref43" ref-type="bibr">43</xref>] In the other study, Yang <italic>et al</italic>. investigate the effect of intratympanic dexamethasone or methylprednisolone on treatment of sudden sensorineural hearing loss in 47 subjects. patients received an at least 7-day dexamethasone(5 g/l/d) or methylprednisolone (40 g/l/d) course. They showed Intratympanic dexamethasone or methylprednisolone can be beneficial in treatment on patient with sudden sensorineural hearing loss, however, there was no significant difference in the effect between dexamethasone and methylprednisolone.[<xref rid="ref40" ref-type="bibr">40</xref><xref rid="ref41" ref-type="bibr">41</xref><xref rid="ref42" ref-type="bibr">42</xref><xref rid="ref43" ref-type="bibr">43</xref><xref rid="ref44" ref-type="bibr">44</xref>]</p><p>In our study based on Siegel's criteria complete recovery in the methylprednisolone group was significantly better than the dexamethasone group (24% vs 12% respectively). It means that according to our results, intratympanic methylprednisolone therapy shows better hearing recovery for sudden sensorineural hearing loss patients without early response to systemic treatment rather than dexamethasone. Both topical intratympanic application of dexamethasone and methylprednisolone are safe and effective methods for the treatment of SSNHL cases that are refractory to conventional therapies.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haberkamp</surname><given-names>TJ</given-names></name><name><surname>Tanyeri</surname><given-names>HM</given-names></name></person-group><article-title>Management of idiopathic sudden sensorineural hearing loss</article-title><source>Am J Otol</source><year>1999</year><volume>20</volume><fpage>587</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">10503580</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianoli</surname><given-names>GJ</given-names></name><name><surname>Li</surname><given-names>JC</given-names></name></person-group><article-title>Transtympanic steroid for treatment of sudden hearing loss</article-title><source>Otolaryngol Head Neck Surg</source><year>2001</year><volume>125</volume><fpage>142</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11555744</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>SD</given-names></name></person-group><article-title>Intratympanic steroids for sensorineural hearing loss</article-title><source>Otolaryngol Clin North Am</source><year>2004</year><volume>37</volume><fpage>1061</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15474111</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>WR</given-names></name><name><surname>Byl</surname><given-names>FM</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double blind clinical study</article-title><source>Arch Otolaryngol</source><year>1980</year><volume>106</volume><fpage>772</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7002129</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shimmer</surname><given-names>BP</given-names></name><name><surname>Parker</surname><given-names>KL</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hardman</surname><given-names>JG</given-names></name><name><surname>Limbird</surname><given-names>LE</given-names></name><name><surname>Molinoff</surname><given-names>PB</given-names></name><name><surname>Gilman</surname><given-names>AG</given-names></name></person-group><article-title>Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones</article-title><source>Goodman and Gilman's the pharmacological basis of the therapeutics</source><year>1996</year><edition>9th ed</edition><publisher-loc>New York, NY</publisher-loc><publisher-name>McGraw-Hill</publisher-name><fpage>1459</fpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>ND</given-names></name><name><surname>Kempton</surname><given-names>JB</given-names></name><name><surname>Trune</surname><given-names>DR</given-names></name></person-group><article-title>Spironolactone blocks glucocorticoid-mediated hearing preservation in autoimmune mice</article-title><source>Laryngoscope</source><year>2002</year><volume>112</volume><fpage>298</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">11889387</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekhar</surname><given-names>SS</given-names></name></person-group><article-title>Intratympanic dexamethasone for sudden sensorineural hearing loss: Clinical and laboratory evaluation</article-title><source>Otol Neurotol</source><year>2001</year><volume>22</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11314710</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopke</surname><given-names>RD</given-names></name><name><surname>Hoffer</surname><given-names>ME</given-names></name><name><surname>Wester</surname><given-names>D</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>MJ</given-names></name><name><surname>Jackson</surname><given-names>RL</given-names></name></person-group><article-title>Targeted topical steroid therapy in sudden sensorineural hearing loss</article-title><source>Otol Neurotol</source><year>2001</year><volume>22</volume><fpage>475</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11449103</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>HG</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Shu</surname><given-names>MT</given-names></name><name><surname>Yang</surname><given-names>CC</given-names></name><name><surname>Tsai</surname><given-names>HT</given-names></name></person-group><article-title>Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment</article-title><source>Laryngoscope</source><year>2004</year><volume>114</volume><fpage>1184</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15235345</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>H</given-names></name><name><surname>Choo</surname><given-names>D</given-names></name><name><surname>Rosenberg</surname><given-names>SI</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Seidman</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>I</given-names></name></person-group><article-title>Intratympanic steroid treatment of inner ear disease and tinnitus (Preliminary Report)</article-title><source>Ear Nose Throat J</source><year>1996</year><volume>75</volume><fpage>468</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8828271</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrs</surname><given-names>DM</given-names></name><name><surname>Keyser</surname><given-names>JS</given-names></name><name><surname>Stallworth</surname><given-names>C</given-names></name><name><surname>McElveen</surname><given-names>JT</given-names><suffix>Jr</suffix></name></person-group><article-title>Intratympanic steroid injections for intractable M&#x000e9;ni&#x000e8;re's disease</article-title><source>Laryngoscope</source><year>2001</year><volume>111</volume><fpage>2100</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11802004</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnes</surname><given-names>LS</given-names></name><name><surname>Sun</surname><given-names>AH</given-names></name><name><surname>Freeman</surname><given-names>DJ</given-names></name></person-group><article-title>Corticosteroid pharmacokinetics in the inner ear fluids: An animal study followed by clinical application</article-title><source>Laryngoscope</source><year>1999</year><volume>109</volume><issue>Suppl 91</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10399889</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Halpin</surname><given-names>C</given-names></name><name><surname>Rauch</surname><given-names>SD</given-names></name></person-group><article-title>Oral steroid treatment of Sudden sensorineural hearing loss: A ten year retrospective analysis</article-title><source>Otol Neurotol</source><year>2003</year><volume>24</volume><fpage>728</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">14501447</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>WR</given-names></name><name><surname>Byl</surname><given-names>FM</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A doubleblind clinical study</article-title><source>Arch Otolaryngol</source><year>1980</year><volume>106</volume><fpage>772</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7002129</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slattery</surname><given-names>WH</given-names></name><name><surname>Fisher</surname><given-names>LM</given-names></name><name><surname>Iqbal</surname><given-names>Z</given-names></name><name><surname>Friedman</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name></person-group><article-title>Intratympanic steroid injection for treatment of idiopathic sudden hearing loss</article-title><source>Otolaryngol Head Neck Surg</source><year>2005</year><volume>133</volume><fpage>251</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16087024</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>DS</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Watford</surname><given-names>K</given-names></name><name><surname>Labadie</surname><given-names>RF</given-names></name></person-group><article-title>Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy</article-title><source>Laryngoscope</source><year>2007</year><volume>117</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17202923</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinamon</surname><given-names>U</given-names></name><name><surname>Bendet</surname><given-names>E</given-names></name><name><surname>Kronenberg</surname><given-names>J</given-names></name></person-group><article-title>Steroids, carbogen or placebo for sudden hearing loss: A prospective doubleblind study</article-title><source>Eur Arch Otorhinolaryngol</source><year>2001</year><volume>258</volume><fpage>477</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">11769996</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merchant</surname><given-names>SN</given-names></name><name><surname>Adams</surname><given-names>JC</given-names></name><name><surname>Nadol</surname><given-names>JB</given-names></name></person-group><article-title>Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss</article-title><source>Otol Neurotol</source><year>2005</year><volume>26</volume><fpage>151</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15793397</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rarey</surname><given-names>KE</given-names></name><name><surname>Luttge</surname><given-names>WG</given-names></name></person-group><article-title>Presence of type I and type II/IB receptors for adrenocorticosteroid hormones in the inner ear</article-title><source>Hear Res</source><year>1989</year><volume>41</volume><fpage>217</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">2530200</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gloddek</surname><given-names>B</given-names></name><name><surname>Lamm</surname><given-names>K</given-names></name><name><surname>Arnold</surname><given-names>W</given-names></name></person-group><article-title>Pharmacological influence on inner ear endothelial cells in relation to the pathogenesis of sensorineural hearing loss</article-title><source>Adv Otorhinolaryngol</source><year>2002</year><volume>59</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11885664</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokroos</surname><given-names>RJ</given-names></name><name><surname>Albers</surname><given-names>FW</given-names></name><name><surname>Schirm</surname><given-names>J</given-names></name></person-group><article-title>The etiology of idiopathic sudden sensorineural hearing loss: Experimental herpes simplex virus infection of the inner ear</article-title><source>Am J Otol</source><year>1998</year><volume>19</volume><fpage>447</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9661753</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagura</surname><given-names>M</given-names></name><name><surname>Iwasaki</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Mizuta</surname><given-names>K</given-names></name><name><surname>Umemura</surname><given-names>K</given-names></name><name><surname>Hoshino</surname><given-names>T</given-names></name></person-group><article-title>Effects of corticosteroid, contrast medium and ATP on focal microcirculatory disorders of the cochlea</article-title><source>Eur J Pharmacol</source><year>1999</year><volume>366</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10064151</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabuchi</surname><given-names>K</given-names></name><name><surname>Oikawa</surname><given-names>K</given-names></name><name><surname>Uemaetomari</surname><given-names>I</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>A</given-names></name></person-group><article-title>Glucocorticoids and dehydroepiandrosterone sulfate ameliorate ischemia-induced injury of the cochlea</article-title><source>Hear Res</source><year>2003</year><volume>180</volume><fpage>51</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12782352</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamm</surname><given-names>K</given-names></name><name><surname>Arnold</surname><given-names>W</given-names></name></person-group><article-title>The effect of prednisolone and non-steroidal anti-inflammatory agents on the normal and noise-damaged guinea pig inner ear</article-title><source>Hear Res</source><year>1998</year><volume>115</volume><fpage>149</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9472744</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Buhi</surname><given-names>WC</given-names></name><name><surname>Alvarez</surname><given-names>IM</given-names></name><name><surname>Curtis</surname><given-names>LM</given-names></name><name><surname>Rarey</surname><given-names>KE</given-names></name></person-group><article-title>De novo synthesis of glucocorticoid hormone regulated inner ear proteins in rats</article-title><source>Hear Res</source><year>1995</year><volume>86</volume><fpage>183</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8567415</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DW</given-names></name><name><surname>Trune</surname><given-names>DR</given-names></name></person-group><article-title>Breakdown of striavascularis blood-labyrinth barrier in C3H/lpr autoimmune disease mice</article-title><source>Otolaryngol Head Neck Surg</source><year>1997</year><volume>117</volume><fpage>530</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9374179</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trune</surname><given-names>DR</given-names></name><name><surname>Wobig</surname><given-names>RJ</given-names></name><name><surname>Kempton</surname><given-names>JB</given-names></name><name><surname>Hefeneider</surname><given-names>SH</given-names></name></person-group><article-title>Steroid treatment improves cochlear function in the MRL. MpJ-Fas(lpr) autoimmune mouse</article-title><source>Hear Res</source><year>1999</year><volume>137</volume><fpage>160</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10545643</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>H</given-names></name><name><surname>Choo</surname><given-names>D</given-names></name><name><surname>Rosenberg</surname><given-names>SI</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Seidman</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>I</given-names></name></person-group><article-title>Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report)</article-title><source>Ear Nose Throat J</source><year>1996</year><volume>75</volume><fpage>468</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">8828271</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parnes</surname><given-names>LS</given-names></name><name><surname>Sun</surname><given-names>AH</given-names></name><name><surname>Freeman</surname><given-names>DJ</given-names></name></person-group><article-title>Corticosteroid pharmacokinetics in the inner ear fluids: An animal study followed by clinical application</article-title><source>Laryngoscope</source><year>1999</year><volume>109</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10399889</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xenellis</surname><given-names>J</given-names></name><name><surname>Papadimitriou</surname><given-names>N</given-names></name><name><surname>Nikolopoulos</surname><given-names>T</given-names></name><name><surname>Maragoudakis</surname><given-names>P</given-names></name><name><surname>Segas</surname><given-names>J</given-names></name><name><surname>Tzagaroulakis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: A control study</article-title><source>Otolaryngol Head Neck Surg</source><year>2006</year><volume>134</volume><fpage>940</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16730534</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plontke</surname><given-names>SK</given-names></name><name><surname>L&#x000f6;wenheim</surname><given-names>H</given-names></name><name><surname>Mertens</surname><given-names>J</given-names></name><name><surname>Engel</surname><given-names>C</given-names></name><name><surname>Meisner</surname><given-names>C</given-names></name><name><surname>Weidner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy</article-title><source>Laryngoscope</source><year>2009</year><volume>119</volume><fpage>359</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">19172627</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>MW</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Yoon</surname><given-names>TH</given-names></name></person-group><article-title>Therapeutic effectiveness over time of intratympanic dexamethasone as salvage treatment of sudden deafness</article-title><source>Acta Otolaryngol</source><year>2008</year><volume>128</volume><fpage>128</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17851916</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kili&#x000e7;</surname><given-names>R</given-names></name><name><surname>Safak</surname><given-names>MA</given-names></name><name><surname>O&#x0011f;uz</surname><given-names>H</given-names></name><name><surname>Kargin</surname><given-names>S</given-names></name><name><surname>Demirci</surname><given-names>M</given-names></name><name><surname>Samim</surname><given-names>E</given-names></name><etal/></person-group><article-title>Intratympanic methylprednisolone for sudden sensorineural hearing loss</article-title><source>Otol Neurotol</source><year>2007</year><volume>28</volume><fpage>312</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17414035</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plaza</surname><given-names>G</given-names></name><name><surname>Herr&#x000b4;aiz</surname><given-names>C</given-names></name></person-group><article-title>Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy</article-title><source>Otolaryngol Head Neck Surg</source><year>2005</year><volume>133</volume><fpage>251</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16087024</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL</article-title><source>Otolaryngol Head Neck Surg</source><year>2009</year><volume>141</volume><fpage>579</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19861194</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>YJ</given-names></name><name><surname>Liang</surname><given-names>JG</given-names></name><name><surname>Wu</surname><given-names>WB</given-names></name><name><surname>Ding</surname><given-names>YF</given-names></name><name><surname>Chiang</surname><given-names>RP</given-names></name><name><surname>Wu</surname><given-names>SM</given-names></name></person-group><article-title>Intratympanic injection with dexamethasone for sudden sensorineural hearing loss</article-title><source>J Laryngol Otol</source><year>2011</year><volume>125</volume><fpage>133</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21054907</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alatas</surname><given-names>N</given-names></name></person-group><article-title>Use of intratympanic dexamethasone for the therapy of low frequency hearing loss</article-title><source>Eur Arch Otorhinolaryngol</source><year>2009</year><volume>266</volume><fpage>1205</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19099315</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seggas</surname><given-names>I</given-names></name><name><surname>Koltsidopoulos</surname><given-names>P</given-names></name><name><surname>Bibas</surname><given-names>A</given-names></name><name><surname>Tzonou</surname><given-names>A</given-names></name><name><surname>Sismanis</surname><given-names>A</given-names></name></person-group><article-title>Intratympanic steroid therapy for sudden hearing loss: A review of the literature</article-title><source>Otol Neurotol</source><year>2011</year><volume>32</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">21192346</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>PA</given-names></name><name><surname>Begg</surname><given-names>EJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Keast</surname><given-names>AT</given-names></name><name><surname>Murray</surname><given-names>DP</given-names></name><name><surname>Balkany</surname><given-names>TJ</given-names></name></person-group><article-title>Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph</article-title><source>Otol Neurotol</source><year>2007</year><volume>28</volume><fpage>1124</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18043438</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plontke</surname><given-names>SK</given-names></name><name><surname>Biegner</surname><given-names>T</given-names></name><name><surname>Kammerer</surname><given-names>B</given-names></name><name><surname>Delabar</surname><given-names>U</given-names></name><name><surname>Salt</surname><given-names>AN</given-names></name></person-group><article-title>Dexamethasone concenration gradients along scala tympani after application to the round window membrane</article-title><source>Otol Neurotol</source><year>2008</year><volume>29</volume><fpage>401</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18277312</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billett</surname><given-names>TE</given-names></name><name><surname>Thorne</surname><given-names>PR</given-names></name><name><surname>Gavin</surname><given-names>JB</given-names></name></person-group><article-title>The nature and progression of injury in the organ of Corti during ischemia</article-title><source>Hear Res</source><year>1989</year><volume>41</volume><fpage>189</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">2808149</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>SH</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Forge</surname><given-names>A</given-names></name><name><surname>Schacht</surname><given-names>J</given-names></name></person-group><article-title>Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals</article-title><source>Hear Res</source><year>2001</year><volume>155</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11335071</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallan</surname><given-names>I</given-names></name><name><surname>De Vito</surname><given-names>A</given-names></name><name><surname>Fattori</surname><given-names>B</given-names></name><name><surname>Casani</surname><given-names>AP</given-names></name><name><surname>Panicucci</surname><given-names>E</given-names></name><name><surname>Berrettini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intratympanic methylprednisolone in refractory sudden hearing loss: A 27-patient case series with univariate and multivariate analysis</article-title><source>Otol Neurotol</source><year>2010</year><volume>31</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19940792</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name></person-group><article-title>The effect of intratympanic dexamethasone or methylprednisolone on treatment of sudden sensorineural hearing loss</article-title><source>Lin Chung Er Bi Yan HouTou Jing Wai Ke Za Zhi</source><year>2010</year><volume>24</volume><fpage>594</fpage><lpage>7</lpage></element-citation></ref></ref-list></back></article>